Payment overview · 2025
General Payments
$363.48
19 reported records · 9 companies
Healthcare provider profile · identity verified
Derek Mason Wedel
Allopathic & Osteopathic Physicians|Family Medicine · SALINA, KS · NPI 1619505872
Verified facts
What the public records show
CMS Open Payments records show Derek Mason Wedel received $363.48 in general payments during 2025 across 19 reported records.
PFIZER INC. accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Arexvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $106.80 | 29.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.79 | 21.9% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $46.61 | 12.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.57 | 9.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.41 | 6.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.51 | 5.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.47 | 5.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.70 | 4.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.62 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $363.48 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $106.80 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $106.80 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $46.61 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 218 | 95 |
| Lisinopril | Lisinopril | 167 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 106 | 44 |
| Omeprazole | Omeprazole | 100 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 97 | 52 |
| Gabapentin | Gabapentin | 91 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 30 |
| Furosemide | Furosemide | 86 | 33 |
| Losartan Potassium | Losartan Potassium | 84 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 26 |
| Metformin Hcl | Metformin Hcl | 72 | 29 |
| Potassium Chloride | Potassium Chloride | 56 | 26 |
| Sertraline Hcl | Sertraline Hcl | 56 | 15 |
| Montelukast Sodium | Montelukast Sodium | 51 | 11 |
| Trazodone Hcl | Trazodone Hcl | 51 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 29 |
| Warfarin Sodium | Warfarin Sodium | 47 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Pregabalin | Pregabalin | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 13 |
| Ozempic | Semaglutide | 38 | suppressed |
| Eliquis | Apixaban | 37 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | 16 |
| Simvastatin | Simvastatin | 33 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 31 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 11 |
| Topiramate | Topiramate | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | 11 |
| Atenolol | Atenolol | 29 | 15 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 11 |
| Prednisone | Prednisone | 29 | 17 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | 11 |
| Meloxicam | Meloxicam | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 22 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 17 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $363.48 · 19 records | PFIZER INC. | ABRYSVO, EVENITY, LEQVIO, Leqembi, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error